Clinical trials: HER2
Pancreatic Cancer, Pancreatic Neoplasm
Gemcitabine, Herceptin and Radiation to Treat Cancer of the Pancreas
This study will examine the safety and effectiveness of the drugs Gemcitabine and Herceptin, given in conjunction with radiation therapy, for treating patients with cancer of the pancreas.
- Trial name
- NCT00005926
- Testing
- Gemcitabine, Herceptin, Radiation therapy
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer, Fatigue
Studying Biological Markers of Fatigue in Women With Residual Invasive Breast Cancer Enrolled on Clinical Trial NSABP-B-45
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to fatigue.
- Trial name
- NCT00914043
- Testing
- gene expression analysis, microarray analysis, polymerase chain reaction
- Sponsor
- NSABP Foundation Inc
HER2-positive Breast Cancer
Four Cycles Taxane With Trastuzumab and Pertuzumab Neoadjuvant Therapy Among Low Risk HER2 Positive Patients
Neoadjuvant therapy in the treatment of breast cancer is not only a means of breast conserving surgery, but also a sensitive scheme for patients, in order to reduce the treatment grade, low toxicity and high efficiency.
- Trial name
- LRNacHER2 (NCT06722599)
- Where
- China
- Volunteers
- 171 people
- Sponsor
- Shu Wang
Breast Cancer
Lapatinib Resistance in Patients With Breast Cancer
RATIONALE: Studying samples of tumor tissue and blood from patients with cancer in the laboratory may help doctors learn more about cancer and the development of drug resistance in patients.
- Trial name
- NCT00898573
- Testing
- lapatinib ditosylate, fluorescence in situ hybridization, gene expression analysis
- Where
- 9 sites in United States
- Sponsor
- Case Comprehensive Cancer Center
Breast Neoplasms
The Efficacy of Fulvestrant in ESR1(Estrogen Receptor 1) Mutated Metastatic Breast Cancer
This is an open-label, single arm, phase II trial to evaluate the efficacy and safety of 500mg Fulvestrant (Faslodex®) in ESR1 mutated postmenopausal women with hormone receptor positive, HER2 negative locally advanced or…
- Trial name
- NCT03202862
- Testing
- Fulvestrant
- Volunteers
- 50 people
- Sponsor
- Fudan University
Breast Cancer
Sunitinib Malate and Exemestane in Treating Postmenopausal Women With Breast Cancer
RATIONALE: Sunitinib malate and exemestane may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Trial name
- NCT00931450
- Testing
- exemestane, sunitinib malate
- Where
- Spain
- Volunteers
- 70 people
- Sponsor
- Institut Català d'Oncologia
Gastric Cancer (GC)
Development and Validation of the Surgical Assessment and Healthcare (SAH) Index for Gastric Cancer Treatment Evaluation
This study develops the Surgical Assessment and Healthcare (SAH) Index, a new tool to fairly evaluate gastric cancer surgery outcomes.
- Trial name
- SAH (NCT07180966)
- Where
- China
- Volunteers
- 780 people
- Sponsor
- Ruijin Hospital
HR+/HER2- Early Breast Cancer
IMPLEMENTING PATIENTS' COMPETENCE IN ORAL EBC THERAPY PERSISTENCE
The goal of this interventional study is to evaluate the effect of standardized patient coaching on treatment adherence among patients taking abemaciclib.
- Trial name
- IMPACT PT (NCT07521202)
- Testing
- Standardized patient coaching
- Where
- Germany
- Volunteers
- 257 people
- Sponsor
- Institut fuer Frauengesundheit
Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer
A Study to Observe the Safety of VYLOY (Zolbetuximab) in People in South Korea With Gastric or Gastroesophageal Junction Cancer.
This study is for people in South Korea who have cancer in or around the stomach (gastric cancer) or cancer where the food pipe (esophagus) joins the stomach, called gastroesophageal junction (GEJ) cancer.
- Conditions
- Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
- Trial name
- NCT06902545
- Testing
- zolbetuximab
- Where
- 15 sites in South Korea
- Volunteers
- 377 people
- Sponsor
- Astellas Pharma Korea, Inc.
HER2 Low Breast Cancers
Clinicopathological Parameters of HER2 Low Breast Cancers
This was a retrospective cohort study which included all histologically proven cases of breast cancer in the 2 years from January 2022- December 2023 at a tertiary care centre.
- Trial name
- NCT06433804
- Testing
- HER2 IHC
- Where
- India
- Volunteers
- 70 people
- Sponsor
- Vardhman Mahavir Medical College And Safdarjung Hospital
Breast Cancer
Observation Only Study Involving Participants Enrolled in the CHAT Trial
The aim of the CHAT study ("An open-label, randomized Phase II study of Herceptin (trastuzumab), Taxotere® (docetaxel) and Xeloda (capecitabine) in combination, versus Herceptin (trastuzumab) plus Taxotere® (docetaxel), in…
- Trial name
- NCT01038466
- Where
- Australia
- Volunteers
- 222 people
- Sponsor
- Contact Asia Pacific
Breast Cancer
A Real-world Efficacy and Safety Study of Amlotinib for HER2-negative Advanced Breast Cancer
This study analyses the efficacy and safety of amlotinib as a study drug in the treatment of HER-2 negative advanced breast cancer in the real world, including the number of treatment lines, monotherapy, combination therapy, and…
- Trial name
- NCT06340165
- Testing
- Anlotinib
- Where
- China
- Volunteers
- 153 people
- Sponsor
- The First Hospital of Jilin University
Gastric Cancer, Gastroesophageal Junction Cancer
Human Epidermal Growth Factor Receptor 2 (HER-2) Status in Gastric and Gastro-Esophageal Junction (GEJ) Carcinoma
The primary objective is to evaluate the concordance between human epidermal growth factor receptor 2 (HER2) status determined by the participating laboratory and by the centralized laboratory.
- Trial name
- NCT02731313
- Testing
- Trastuzumab
- Where
- 19 sites in France
- Volunteers
- 420 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer
Pyrotinib Combined With Capecitabine in HER-2 Positive Advanced Breast Cancer and Brain Metastases (Post-PERMEATE)
This study aims to describe the different treatment time, treatment mode and clinical outcomes of pyrotinib maleate tablets combined with capecitabine in the treatment of patients with HER-2 positive advanced breast cancer with…
- Trial name
- NCT05359120
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Henan Cancer Hospital
Breast Cancer
A Study to Learn About the Safety of TALZENNA for the Treatment of Breast Cancer
The purpose of this study is to learn about the safety of TALZENNA for the patients with breast cancer that cannot be removed by surgery and has come back.
- Trial name
- NCT06735742
- Where
- Japan
- Volunteers
- 3 people
- Sponsor
- Pfizer
Radiomic, Radiomics
RADIomics to Predict HER2 Status And T-DXd Efficacy in Metastatic Breast Cancer: the RADIOSPHER2 Study
RADIOSPHER2 study is a monocentric, retrospective, observational study aiming at identifying a radiomics signature able to predict HER2 expression (0 vs low vs overexpression) and trastuzumab deruxtecan efficacy in metastatic…
- Conditions
- Radiomic, Radiomics, Breast Cancer Metastatic, Breast Cancer Stage IV
- Trial name
- RADIOSPHER2 (NCT07030569)
- Testing
- Trastuzumab deruxtecan (DS-8201a)
- Where
- Italy
- Volunteers
- 500 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Breast Neoplasms
Analysis of Brain Metastasis in Patients With Breast Cancer, With and Without Over-Expression of HER-2
This study will examine two subsets of patients with breast cancer metastasis, that is, spreading, to the brain. It will identify genes and proteins that promote metastasis, particularly in women who are found to over-express…
- Trial name
- NCT00071383
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Breast Cancer
A Study of Patients With HER2-Positive Metastatic Breast Cancer
This is a prospective observational cohort study designed to describe effectiveness and safety (treatment outcomes and clinically significant cardiac adverse events, respectively) in patients with HER2-positive metastatic breast…
- Trial name
- NCT00105456
- Volunteers
- 1,000 people
- Sponsor
- Genentech, Inc.
Breast Cancer
Tolerability and Efficacy of Adjuvant T-DM1 in Patients with HER2 Positive Breast Cancer After Incomplete Pathological Response to Neoadjuvant Chemotherapy Including Anti-HER2 Agents.
Multicenter, retrospective-prospective, real-world observational study, with the aim of evaluating tolerability and efficacy in a population of patients treated according to clinical practice outside of studies randomized.
- Trial name
- ATD (NCT06272799)
- Testing
- T-DM1 adjuvant
- Where
- Italy
- Volunteers
- 160 people
- Sponsor
- Regina Elena Cancer Institute
Breast Cancer
LYNPARZA Breast Cancer in the Adjuvant Setting Japan Post-Marketing Surveillance (PMS)
To evaluate the frequency of bone marrow suppression Adverse Drug Reactions (ADRs) in patients with BRCA mutated HER2 negative high recurrent risk breast cancer treated with LYNPARZA for adjuvant treatment in the actual…
- Trial name
- NCT05677308
- Where
- 38 sites in Japan
- Volunteers
- 61 people
- Sponsor
- AstraZeneca